TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05712382

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping with negative emotions
Description: Mindfulness-based techniques are taught to improve ability to cope with negative emotions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping with negative emotions
Description: Mindfulness-based techniques are taught to improve ability to cope with negative emotions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping with negative emotions
Description: Mindfulness-based techniques are taught to improve ability to cope with negative emotions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping with negative emotions
Description: Mindfulness-based techniques are taught to improve ability to cope with negative emotions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping with negative emotions
Description: Mindfulness-based techniques are taught to improve ability to cope with negative emotions.
Study: NCT05162105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short rest (8 hour) between two consecutive shifts.
Description: Participants will have shortened rest opportunity (8 hours) between two consecutive shifts, due to the shift work schedule.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 16 hour rest opportunity between to consecutive shifts.
Description: Participants will have a 16 hour rest opportunity between shifts, due to shift work schedule.
Study: NCT05336422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training on the risks associated with sun exposure
Description: 15-minute power point and presentation on the risks of sun exposure
Study: NCT05184894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AKI in Care Transitions (ACT) program
Description: Multicomponent transitional support bundle that includes consultation from nurse educators before discharge to deliver kidney health education and coordination of appointments post-discharge.
Study: NCT05958537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen
Description: Use of High-flow nasal oxygen at 60% 50 L/min.
Study: NCT04822259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JOURNEY II BCS Total Knee System
Description: Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II BCS Total Knee System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JOURNEY II CR Total Knee System
Description: Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II CR Total Knee System
Study: NCT05489289

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AK104
Description: Subjects will receive AK104 until disease progression or for a maximum of 16 cycles

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will receive placebo until disease progression or for a maximum of 16 cycles
Study: NCT05035394

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Cataract Surgery in a standardized fashion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: KDB
Description: Goniotomy with KDB glide will be performed at the end of Cataract Surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Istent
Description: Two iStent inject W will be injected into Schlemms Canal at the end of Cataract Surgery
Study: NCT05747469

Intervention type: DRUG
Group type: OTHER
Intervention: local anaesthetic injection
Description: Subcutaneous local anesthesia with 1% lidocaine without epinephrine is administered to the skin overlying the joint.
Study: NCT05712382

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping with negative emotions
Description: Mindfulness-based techniques are taught to improve ability to cope with negative emotions.
Study: NCT05747469

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Human Adipose Allograft
Description: Light axial traction of the digit is used to open the joint space when introducing the 18-gauge needle. Fluoroscopy is used to assist with visualization 1 cc of Leneva is injected into the CMC joint and 0.5 cc in the IP, PIP and DIP joints. The puncture is dressed with a band-aid and coban wrap, which will be worn for 48 hours. Return to work and normal use of the hand is recommended at 48 hours. No narcotics are prescribed.
Study: NCT06348212

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei PS23
Description: 2 caps daily use

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: microcrystalline cellulose
Description: 2 caps daily use
Study: NCT04715100

Intervention type: OTHER
Intervention: Observational group
Description: The study dependent variables will be: pain (vas scale), joint status (Hemophilia Joint Health Score), perception of quality of life (SF-36 questionnaire), list of roles (Oakley questionnaire), performance of basic activities of daily life (Barthel index) and the performance of instrumental activities of daily living (Lawton and Brody scale).
Study: NCT04234542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Each stage will follow this sequence of applications: (1) spine application (DUO-240 red and infrared array in a horizontal placement and 2 oblique placements bilaterally + LDR-100 laser probe + LDI-200 laser probe), (2) perineum application (DUO-240 red and infrared array in the surface of the perineum + LDR-100 probe) and (3) overlying branches of the pudendal nerve at the lateral perineum (LDI-200 probe). Parameters of frequency and duty cycle will be increased along with intensity as the stages progress.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Low Level Laser Therapy
Description: Each stage will follow this sequence of applications: (1) spine application (DUO-240 red and infrared array in a horizontal placement and 2 oblique placements bilaterally + LDR-100 laser probe + LDI-200 laser probe), (2) perineum application (DUO-240 red and infrared array in the surface of the perineum + LDR-100 probe) and (3) overlying branches of the pudendal nerve at the lateral perineum (LDI-200 probe). Parameters of frequency and duty cycle will be progressed, but power will always be set to 1%..
Study: NCT06304571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC006
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC006
Description: Specified dose on specified days
Study: NCT04784975

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05649774

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Only Myofascial Release will be provided

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Taping technique
Description: Only Kinesiotaping will be provided

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapy with taping
Description: Myofascial release will be provided followed by Kinesiotaping

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: Placebo Treatment will be given
Study: NCT04630262

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATTUNE Cementless CR Fixed Bearing
Description: Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and CR or (Medial Stabilized) MS Tibial Insert.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATTUNE Cementless PS Fixed Bearing
Description: Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and PS Tibial Insert.
Study: NCT05509374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib 56 MG [Kyprolis]
Description: Carfilzomib 56 mg/m2 (Day1, 8, 15) (Cycle1 Day1, 20 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide 4 mg per os (Day1-21)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg (D1, 8, 15, 22) (20 mg for patients ≥ 75 years old)
Study: NCT04678310

Intervention type: OTHER
Intervention: Support from the hospital palliative and end of life care volunteer service (developed for this study).
Description: Hospital palliative and end of life care volunteer service: a volunteer service to provide support to patients dying in the hospital and their families. The volunteer service has been designed to provide presence and companionship to dying patients at the end of life, and their families.
Study: NCT05345587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THESS monitoring
Description: Consultation with the pharmacist to look for possible medication interactions between the oral therapy and the patient's usual treatments and to inform the patient about his treatment to improve QOL and compliance. Consultation and follow-up by a nurse. Weekly notification by THESS Application of the symptoms experienced by the patient over the last 7 days
Study: NCT05673655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intraoral trigger point injection by botox
Description: intraoral injection of trigger point of masseter muscle by botulinum toxin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous trigger point injection by botox
Description: transcutaneous injection of masseter muscle by botulinum toxin
Study: NCT05058456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Medical Mini S Peripheral IVL Catheter
Description: The Shockwave Medical Mini S Peripheral IVL Catheter is intended for lithotripsy-enhanced catheter dilatation of lesions, including calcified lesions found in the peripheral vasculature, such as the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. The Mini S IVL Catheter is not for use in the coronary or cerebral vasculature.
Study: NCT06736977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Onsite Nurse-Led Education Programme on IPC
Description: The programme was designed to enhance CCWs' IPC knowledge and attitudes through lectures, interactive discussions, information sharing, and Q\&A sessions. It also aims to improve their IPC practices and self-efficacy through demonstrations, role-playing exercises, and a work assignment focused on IPC self-monitoring.~The programme includes five educational sessions totalling 12 hours, along with one session for work assignment on daily self-monitoring of IPC practices over five days. The educational sessions cover the following topics:~1. General concepts of infectious diseases~2. Vaccination~3. Standard precautions: The use of personal protective equipment, environmental cleaning and disinfection, handling food and feeding, and waste management~4. Standard precautions: Hand hygiene~5. Common infectious diseases in DCCs and management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Online Nurse-Led Education Programme on IPC
Description: The online version of the nurse-led education programme was conducted using an online meeting platform. It includes the same content, learning activities, and materials as the onsite delivery programme, except for the practice stations, which cannot be provided to participants in the online delivery. Additionally, all documents will be available for download via the online platform.
Study: NCT06736717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: 20 or30mg flat dose - depending on results from safety lead-in. Administered concurrently with NALIRIFOX.~Once daily on D1-5 of each 14-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NALIRIFOX
Description: Chemotherapy regimen of nanoliposomal irinotecan, oxaliplatin, fluorouracil \[5-FU\], and leucovorin.~Intravenously on Day 1 of each 14-day cycle.
Study: NCT04783727

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Individualised treatment duration based on RNA transcriptomic model
Description: Anti-MDR-TB treatment with standard drugs and individual treatment duration guided by the RNA transcriptomic model; may be shorter or longer than standard WHO-recommended treatment duration of 20 months.
Study: NCT06432426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality training group
Description: Participants will be given virtual reality games on Nintendo Wii Fit® and its peripheral Balance Board system. This equipment offers safe and engaging training protocols. Additionally, it ensures physical exercise in the three planes of movement (sagittal, frontal, and transverse) and with three difficulty levels, thus providing a linear progressive demand.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical exercise group
Description: Participants will be submitted to a standard physical exercise program based on the ACSM guidelines. Resistance training will involve exercises for arms and legs, using bodyweight self-loading and external weights. Balance exercises will include the three planes of movement.
Study: NCT04856618

Intervention type: BIOLOGICAL
Intervention: Massive Transfusion of Allogeneic Blood
Description: Massive Transfusion of Allogeneic Blood, \> pRBCs
Study: NCT04791826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-screen electronic alert
Description: On-screen computer-based alert notifying the provider that the patient is at an increased risk of developing HF based on the WATCH-DM risk score and associated guideline recommendation for preventive management of these patients.
Study: NCT06413394

Intervention type: OTHER
Intervention: environmental education
Description: environmental education

Intervention type: OTHER
Intervention: environmental education
Description: environmental education
Study: NCT05544955

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: isolate whey protein prior to and immediately after resistance training
Description: This arm involved protein ingestion immediately prior to and immediately after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: isolate whey protein 3 hours prior to and 3 hours after resistance training
Description: This arm involved protein ingestion 3 hours prior to and 3 hours after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
Study: NCT06737042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR18
Description: GLP-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR18
Description: GLP-1
Study: NCT05551988

Intervention type: OTHER
Intervention: Retrospective observational study of diabetic foot ulcer
Description: This is a retrospective observational study of antibiotic resistance and risk factors of amputation in diabetic foot ulcer patients
Study: NCT06444100

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Impact of structural training on child abuse
Description: A focus group discussion to delve into teachers' perceptions of child abuse. Based on the findings, the training module will be modified as need-based.~Phase II: Randomly selected samples will be invited, with the researcher explaining the study procedures and obtaining verbal and written consent from teachers and assent from children. A dedicated room will be arranged for data collection, and participants will be instructed on how to respond to child abuse questions on tablets.~Phase-III A pretest will be conducted to assess the existing knowledge level and attitude of the teachers toward child abuse. A 5-hour training session, led by an expert team, will follow the pretest questionnaire administration to all participants. Teachers will also be educated on how to report instances of child abuse. A post-test will be administered using the same questionnaires two weeks after the training.
Study: NCT05371197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with PD-L1 inhibitor
Description: Neoadjuvant therapy with PD-L1 inhibitor (Envafolimab), 300mg, Q3W for 4 cycles
Study: NCT06500715

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture will be administered bilaterally on points PC6, LI 4, CV6, SP6, SP10 and ST36 on the first day of each cycle (d1), prior to administration of chemotherapy; and on d8, each session lasting between 30 to 45 minutes. Patients will continue from d1 to d8 with press-tack acupuncture needles on points PC 6, LI4, SP 6 and ST 36. On d8, patients will again undergo acupuncture, and continue with self-acupressure on the same points as the press-tack needles, until the next chemotherapy cycle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture will be administered bilaterally on points PC6, LI 4, CV6, SP6, SP10 and ST36 on the first day of each cycle (d1), prior to administration of chemotherapy; and on d8, each session lasting between 30 to 45 minutes. Patients will continue from d1 to d8 with press-tack acupuncture needles on points PC 6, LI4, SP 6 and ST 36. On d8, patients will again undergo acupuncture, and continue with self-acupressure on the same points as the press-tack needles, until the next chemotherapy cycle.
Study: NCT04105660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training for EEG monitoring
Description: Training for reading EEG curves during anaesthesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard monitoring
Description: Standard monitoring including clinical parameters and BIS index

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard monitoring
Description: Standard monitoring including clinical parameters and BIS index
Study: NCT05016050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPDT-DA-013
Description: Digital program with therapeutic interventions based on Cognitive Behavioral Therapy (CBT).
Study: NCT05796973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided physical exercise
Description: Patients will be participating in guided physical exercise program regularly two times / week at a sports facility and guided by a professional trainer. They will participate in aerobic and resistance exercises during the sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided physical exercise
Description: Patients will be participating in guided physical exercise program regularly two times / week at a sports facility and guided by a professional trainer. They will participate in aerobic and resistance exercises during the sessions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Patients will be participating in guided physical exercise program regularly two times / week at a sports facility and guided by a professional trainer. They will participate in aerobic and resistance exercises during the sessions. In addition to the exercise program they will be given atorvastatin 40 mg QD medication.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Independent exercise
Description: The control group is advised of the benefits of physical exercise and they get an exercise program to follow. Participants in the control group exercise on their own.
Study: NCT05768464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg intravenously every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5mg orraly twice daily
Study: NCT05644483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam: loading (6mg/kg/hr) + continuous infusion (1-2mg/kg/hr)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol: target controlled infusion: 2-3mcg/mL
Study: NCT06473818

Intervention type: DEVICE
Intervention: Non-invasive monitoring
Description: Non-invasive cardiac output monitoring

Intervention type: DEVICE
Intervention: Invasive monitoring
Description: Invasive cardiac output monitoring
Study: NCT04373070

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: CAir
Description: The CAir desk is a custom-built home disease monitoring device. The device consists of a smartphone (A320 \[2017\], Samsung Group, Seoul, Korea), home spirometer (Air Next Spirometer, NuvoAir, Stockholm, Sweden), physical activity tracker (Charge 3, Fitbit Inc., San Francisco CA, USA), and an air-quality monitor (Foobot, Airboxlab, Esch sur Alzette, Luxembourg). The components of the CAir desk are CE-certified.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CAir
Description: The CAir desk is a custom-built home disease monitoring device. The device consists of a smartphone (A320 \[2017\], Samsung Group, Seoul, Korea), home spirometer (Air Next Spirometer, NuvoAir, Stockholm, Sweden), physical activity tracker (Charge 3, Fitbit Inc., San Francisco CA, USA), and an air-quality monitor (Foobot, Airboxlab, Esch sur Alzette, Luxembourg). The components of the CAir desk are CE-certified.
Study: NCT05551221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin Capsules
Description: Silodosin is a α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieves the dynamic obstruction of bladder outlet, and improves the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule，1 capsule/time, bid, after breakfast and dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin Capsules
Description: Silodosin is a α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieves the dynamic obstruction of bladder outlet, and improves the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule，1 capsule/time, bid, after breakfast and dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ningmitai capsule
Description: Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.